Vemurafenib
About
Therapy type: Targeted therapy
Therapy strategy: B-RAF inhibition
Mappings
NCI Thesaurus: Vemurafenib (coding:ncit:C64768)
RxNorm: vemurafenib (coding:rxcui:1147220, coding:omop:40241937)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | BRAF p.V600E | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| FDA (2) | BRAF p.V600K | Melanoma | Atezolizumab, Cobimetinib, Vemurafenib | |
| EMA (1) FDA (2) | BRAF p.V600E | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (1) FDA (2) | BRAF p.V600K | Melanoma | Cobimetinib, Vemurafenib | |
| EMA (1) FDA (2) | BRAF p.V600E | Melanoma | Vemurafenib | |
| FDA (2) | BRAF p.V600E | Erdheim-Chester Disease | Vemurafenib | |
| FDA (2) | BRAF p.V600K | Erdheim-Chester Disease | Vemurafenib | |
| EMA (1) | BRAF p.V600K | Melanoma | Vemurafenib |